InvestSMART

Actinogen Medical Limited (ASX: ACW) - Announcements

Current share price for ACW : $0.041 0.002 (4.65%)+

ASX company news and announcements for Actinogen Medical Limited (ACW) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Actinogen Medical Limited (ACW) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Actinogen Medical Limited (ACW), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Actinogen Medical Limited (ACW)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$159 Letter to Shareholders, Notice of AGM & Proxy Form 28 Oct 2026 10:57AM $0.041 $0.041 fallen by 0%
$159 Actinogen receives $10.8m R&D tax incentive rebate from ATO 26 Oct 2026 2:16PM $0.044 $0.041 fallen by 6.82%
$159 ACW pivotal Alzheimers trial database lock - results mid-Nov 21 Oct 2026 8:55AM $0.043 $0.041 fallen by 4.65%
$159 ACW September 2026 quarterly activity report & Appendix 4C 19 Oct 2026 9:57AM $0.045 $0.041 fallen by 8.89%
$159 Notification of buy-back - ACW 12 Oct 2026 12:41PM $0.053 $0.041 fallen by 22.64%
$159 AGM date and closing date for director nominations 9 Oct 2026 9:10AM $0.053 $0.041 fallen by 22.64%
$159 Application for quotation of securities - ACW 30 Sep 2026 1:04PM $0.059 $0.041 fallen by 30.51%
$159 Options underwriting cleansing notice 23 Sep 2026 12:35PM $0.062 $0.041 fallen by 33.87%
$159 Application for quotation of securities - ACW 23 Sep 2026 12:35PM $0.062 $0.041 fallen by 33.87%
$159 Underwriting of unlisted options completed 23 Sep 2026 12:34PM $0.062 $0.041 fallen by 33.87%
$159 ACW Alzheimers pivotal trial completes last patient visit 23 Sep 2026 8:47AM $0.058 $0.041 fallen by 29.31%
$159 Notification of cessation of securities - ACW 16 Sep 2026 12:43PM $0.056 $0.041 fallen by 26.79%
$159 Application for quotation of securities - ACW 15 Sep 2026 2:34PM $0.059 $0.041 fallen by 30.51%
$159 Application for quotation of securities - ACW 11 Sep 2026 3:54PM $0.058 $0.041 fallen by 29.31%
$159 Appendix 3Y-Dr Geoffrey Brooke 9 Sep 2026 12:54PM $0.061 $0.041 fallen by 32.79%
$159 Application for quotation of securities - ACW 9 Sep 2026 12:40PM $0.061 $0.041 fallen by 32.79%
$159 ACW CMO international Xanamem presentation 9 Sep 2026 10:11AM $0.064 $0.041 fallen by 35.94%
$159 Application for quotation of securities - ACW 8 Sep 2026 2:52PM $0.063 $0.041 fallen by 34.92%
$159 Application for quotation of securities - ACW 7 Sep 2026 4:39PM $0.059 $0.041 fallen by 30.51%
$159 Response to ASX Price Query 4 Sep 2026 3:55PM $0.054 $0.041 fallen by 24.07%
$159 Application for quotation of securities - ACW 3 Sep 2026 3:04PM $0.049 $0.041 fallen by 16.33%
$159 Proposed issue of securities - ACW 1 Sep 2026 10:14AM $0.044 $0.041 fallen by 6.82%
$159 ACW unlisted options fully underwritten 1 Sep 2026 10:12AM $0.044 $0.041 fallen by 6.82%
$159 Application for quotation of securities - ACW 28 Aug 2026 3:58PM $0.043 $0.041 fallen by 4.65%
$159 Appendix 3Y-Dr George Morstyn 28 Aug 2026 2:46PM $0.043 $0.041 fallen by 3.53%

1 - 25 of 917 results

Page 1 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.